Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL)
| Assets | $9.62M |
| Expense Ratio | 0.97% |
| PE Ratio | n/a |
| Shares Out | 1.65M |
| Dividend (ttm) | $0.08 |
| Dividend Yield | 1.47% |
| Ex-Dividend Date | Jun 24, 2025 |
| Payout Frequency | Quarterly |
| Payout Ratio | n/a |
| Volume | 75,487 |
| Open | 5.90 |
| Previous Close | 5.96 |
| Day's Range | 5.64 - 5.90 |
| 52-Week Low | 3.62 |
| 52-Week High | 10.62 |
| Beta | 1.72 |
| Holdings | 49 |
| Inception Date | Nov 15, 2017 |
About PILL
Fund Home PageThe Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) is an exchange-traded fund that is based on the S&P Pharmaceuticals Select Industry index. The fund provides 3x daily exposure to a modified equal-weighted index of pharmaceutical companies in the US. PILL was launched on Nov 15, 2017 and is issued by Direxion.
Top 10 Holdings
53.05% of assets| Name | Symbol | Weight |
|---|---|---|
| Goldman Sachs Fin Gov 465 Institut | n/a | 13.73% |
| S&P Pharmaceuticals Select Index Swap | n/a | 9.33% |
| Goldman Sachs Financial Square Treasury Instruments Fund | FTIXX | 7.64% |
| Dreyfus Govt Cash Man Ins | n/a | 6.12% |
| Pfizer Inc. | PFE | 2.75% |
| Royalty Pharma plc | RPRX | 2.74% |
| Elanco Animal Health Incorporated | ELAN | 2.72% |
| Viatris Inc. | VTRS | 2.71% |
| Merck & Co., Inc. | MRK | 2.66% |
| Johnson & Johnson | JNJ | 2.64% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Jun 24, 2025 | $0.02449 | Jul 1, 2025 |
| Mar 25, 2025 | $0.01829 | Apr 1, 2025 |
| Dec 23, 2024 | $0.01305 | Dec 31, 2024 |
| Sep 24, 2024 | $0.02872 | Oct 1, 2024 |
| Jun 25, 2024 | $0.02194 | Jul 2, 2024 |
| Mar 19, 2024 | $0.02716 | Mar 26, 2024 |
Performance
PILL had a total return of -9.45% in the past year, including dividends. Since the fund's inception, the average annual return has been -16.12%.
News
Seeking Stocks With Vitality In The Volatile Healthcare Sector
Investors cooled to the healthcare sector in 2024, which dramatically trailed global and US equity markets for the year. any investors are now asking: how will the policy changes under a new US admini...
Biotech Innovations Remain At Forefront
The first quarter of 2021 was challenging for the biotechnology industry, as the selloff in March represented a sharp reversal from record highs in February. While the sector has remained relatively r...
3 Pharmaceutical ETFs That Could Be Due For A Rebound
These three pharmaceutical ETFs have dropped to support, which means they may be about to rebound. Support is a large concentration of buyers who have gathered around the same price level.
Moving Beyond COVID In Biopharma
Just over one year after COVID-19 disrupted our lives, we are now getting to the point where multiple vaccine options are nearly ubiquitous for those in the United States. Per the CDC, as of April 12,...
Healthcare: A Wide Choice Of Large And Well-Established Companies
The advantage for dividend investors in this sector is the wide choice of large and well-established companies. AbbVie is a drug company with strong exposure to the immunology and the oncology markets...
3 Leveraged Healthcare ETFs Soaring This Month
The new coronavirus from China has claimed more than 800 lives and there are now more than 37,000 documented cases of the respiratory illness worldwide, making it more deadly than the 2003 SARS epidem...
With Earnings On Tap, A Stir In This Leveraged Pharmaceuticals ETF
With pharmaceuticals stocks under intense political scrutiny this year, the Dynamic Pharmaceutical Intellidex Index (DZRTR) is lower by nearly 8% and is on pace for one of its worst annual performance...